Skip to main contentSkip to navigationSkip to search
Curasight

Important information

The information contained in this section of the website of Curasight A/S (the "Company") (a) is only intended for, and may only be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the "United States"), Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regulations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any ordinary shares or other securities of the Company in the United States, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which such release, publication or distribution would be unlawful. If you are unable, or have any doubt whether you are able, to provide the necessary confirmation you should press "No" and you will not be able to view information about the offering.

In particular, the information does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, or form part of any offer, invitation or solicitation to purchase, securities to any person in the United States. The shares of the Company referred to in this section of the website (the "Shares") have not been and will not be registered under the Securities Act and may not be offered or sold within the United States absent registration under the Securities Act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register any Shares in the United States or to make a public offering of the Shares in the United States. Furthermore, the Shares have not been and will not be registered under the applicable securities laws of Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures.

Access to the information and documents contained on the following section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorised to access such information and documents. All persons residing outside of Denmark who wish to have access to the documents contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained outside Denmark. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

The contents of this website are not to be incorporated into, or construed to form part of, any of the documents included herein. Except as otherwise explicitly stated herein as applicable to them, no information included on this website should be used by investors in forming their investment decision as to an investment in the Shares.

The use of this section of the website is subject to Danish law and any disputes arising out of or regarding this section of the website is subject to Danish law and the exclusive jurisdictions of the Danish courts.

I therefore certify that each of the following is true and accurate:

  1. I am resident and physically present outside the United States, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa; and
  2. I am resident and physically present
    1. in Denmark or
    2. outside Denmark, the United States, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and, in that case, I am authorized to access the information and documents on this website without being subject to any legal restriction and without any further action required by the Company; and
  1. I have read, understand and agree to comply with all of the restrictions set forth above. I understand that the disclaimer may affect my rights and I accept to be bound by the disclaimer. By clicking "Yes", I confirm that I have permission to access the electronic versions of the information.

The information contained in this section of the website of Curasight A/S (the "Company") is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part in, into or from the United States of America (including its territories and possessions), any state of the United States and the District of Columbia, Australia, Hong Kong, Japan, Canada, New Zealand or South Africa, or any other jurisdiction in which such release, publication or distribution would be unlawful.

Rights Issue 2024

The proceeds of the Rights Issue are intended to be used to strengthen Curasight’s capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen the company’s business development and broadening the pipeline through development of new therapeutic peptides.

Documents

The subscription period in Curasight’s rights issue begins today (February 23, 2024)

Subscription without subscription rights (overtegningsformular)

For oversubscription without subscription rights, please contact your bank. If your bank cannot handle oversubscriptions electronically you can fill out the subscription form (download) , and send to your bank.

Please make sure it’s sent to your bank’s back office – Nordic Issuing will not be able to accept subscription forms sent from your personal adviser within the bank.

Overtegningsformular - Curasight

Curasight publishes information memorandum in connection with forthcoming rights issue (February 22, 2024)

Press release: Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy (February 13, 2024)

Annual report 2023

Annual report 2022

Annual report 2021

Link to articles of association

Investor Presentation

View a presentation in connection with the rights issue by Curasight’s CEO Ulrich Krasilnikoff and CSO Andreas Kjær

Details of the Rights Issue

Full terms and conditions for the Rights Issue as well as other information about the Company will be included in the Information Memorandum that the Company expects to publish around the time of 22nd February 2024.

Information memorandum regarding Curasight A/S (February 22, 2024)

Important Dates

DATEEvent
20 February 2024Last day of trading in the share including the right to receive subscription rights
21 February 2024First day of trading in the share excluding the right to receive subscription rights
21 February – 5 March 2024Trading in subscription rights
22 February 2024Record date for the Rights Issue
22 February 2024Estimated date for the publication of the Information Memorandum
23 February – 7 March 2024Subscription period
23 February until the Rights Issue is registered with the Danish Business AuthorityTrading in temporary shares
Around 12 March 2024Estimated publication of the outcome in the Rights Issue

Contacts

Questions about the offer

Nordic Issuing AB
info@nordic-issuing.se
+46 40 632 00 20

Questions about the company

Curasight A/S
info@curasight.com
+45 22 83 01 60

Questions and Answers

How can I participate in the rights issue?

You can participate in the rights issue by exercising your subscription rights through your custodian bank or broker. Subscription rights are traded on Spotlight Stock market and additional rights can thus be acquired over market.

The general public and existing shareholders can subscribe for any Remaining Shares that have not been subscribed in the issue. You can subscribe by completing a subscription form, which is available on Curasight’s website (www.curasight.com), Redeye’s website (www.redeye.se) and Nordic Issuing’s website (www.nordic-issuing.se). The subscription form needs to be completed and submitted to the account holder’s own bank according to their instructions.

Why should I participate in the Rights Issue?

Participating in the rights issue supports Curasight by providing the company with new funds, aiding Curasight’s accelerated strategy and ongoing clinical trials. In contrast, acquiring shares on the stock market lacks this direct benefit, as the funds exchanged occur solely between investors without benefiting the company itself.

Therefore, by subscribing to the Rights Issue, you actively support Curasight and contribute to the company’s mission of pioneering theranostic approaches to diagnose and treat certain types of cancer with the aim of providing clinicians and patients with innovative solutions.

Can I purchase more shares than my current shareholding allows for?

Yes, you can purchase more shares than your current shareholding allows for, by acquiring additional subscription rights (if available) in the market during the rights trading period.

The general public and existing shareholders can subscribe for any Remaining Shares that have not been subscribed in the issue. Subscription shall be made via the completion of a subscription form, which is available on Curisight’s website (www.curasight.com), Redeye’s website (www.redeye.se) and Nordic Issuing’s website (www.nordic-issuing.se). The subscription form must be completed and submitted to the account holder’s own bank according to their instructions.

I would like to participate, but for fewer shares than my current shareholding allows for

You can subscribe for fewer shares than your current shareholding allows for by exercising only a portion of your subscription rights during the subscription period.

What do I do if I do NOT want to participate in the Rights Issue?

If you do not want to participate in the Rights Issue, you can choose not to exercise your subscription rights during the subscription period. Alternatively, you may also sell your subscription rights on the market during the rights trading period.

Is it possible to change or annul an order during the period where the Rights Issue is open?

No, once you have exercised your subscription rights and placed your order for new shares, it cannot be changed or annulled. The subscription is binding.

Can I participate even though I am not a current shareholder in Curasight?

Yes, the general public can participate in the rights issue by subscribing for any remaining shares after existing shareholders have exercised their subscription rights, subject to availability. Furthermore, subscription rights are traded on Spotlight stock market, meaning that subscription rights can be acquired over market.

Are there any costs for me to participate in the Rights Issue?

There may be fees charged by your custodian bank or broker for participating in the Rights Issue, and you would also need to pay the subscription price for the new shares you are acquiring.

What are the tax implications for me if I participate in the Rights Issue?

The tax implications of participating in the Rights Issue would depend on your individual tax jurisdiction and circumstances. It's advisable to consult with a tax advisor to understand any potential tax implications